

Definition & Staging of CKM Syndrome

Carolyn Lam

Disclosures

Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore;

has Received research support from NovoNordisk and Roche Diagnostics;

has Served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopetents, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Hanmi, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai;

and serves as Co-founder & non-executive director of Us2.ai.


Definition of CKM Syndrome

Cardiovascular-kidney-Metabolic (CKM) syndrome is a health disorder due to connections among heart disease, kidney disease, diabetes and obesity leading to poor health outcomes.

CKM syndrome includes both individuals at risk for CVD, and individuals with existing CVD




CKM Syndrome: Multisystem Consequences



Ndumele CE, Neeland IJ, Tuttle KR, et al. *Circulation*. 2023;148(20):1636-1664.

Strong epidemiological overlap of Cardiovascular, Metabolic, and Kidney disorders




Novel CKM staging model

Stage 0: No Risk Factors




A focus on
primordial prevention
and preserving
cardiovascular health


Novel CKM staging model




Novel CKM staging model




Novel CKM staging model



Novel CKM staging model



Strong epidemiological overlap of Cardiovascular, Metabolic, and Kidney disorders



Rationale for CKM Syndrome Staging

Reflects the pathophysiology of underlying CKM progression

Importance of early detection of under-recognized clinical conditions

Each stage to represent a higher level of absolute clinical risk

Principal focus on cardiovascular disease

The primary cause of premature mortality in relation to poor CKMH is CVD.

Additional focus on kidney failure

Each stage represents an opportunity for preventive intervention

The goal is to prevent the progression to the next stage